Invest in simplicity with the BD Veritor™ Plus System for RSV.
Simple RSV testing for those at highest risk.
The portable, easy-to-use BD Veritor™ Plus System for Rapid Detection of RSV provides reliable results in 10 minutes.1
When your pediatric patients** need fast, reliable RSV testing, turn to the BD Veritor™ Plus System. Offering reliable results at point of care in a simple-to-operate, handheld instrument.
BD Veritor™ Plus System for Rapid Detection of
RSV (CLIA-waived kit) offers proven performance
| PPA† | NPA‡ | Results in | |
|---|---|---|---|
| Compared to viral culture | 91.8% (95% C.I. 85.9%, 95.4%) | 93.3% (95% C.I. 90.4%, 94.4%) | 10 minutes
|
| Compared to PCR | 81.6% (95% C.I. 75.2%, 86.6%) | 99.1% (95% C.I.97.5%, 99.7%) | 10 minutes
|
†positive percent agreement
‡negative percent agreement
| Ordering information | Cat no. | Qty |
|---|---|---|
| BD Veritor™ Plus System RSV CLIA-waived kit | 256038 | 30 tests |
| BD Veritor™ Plus System RSV moderately complex kit | 256042 | 30 tests |
| BD Veritor™ Plus Analyzer | 256066 | 1 unit |
Get more answers with every sample
Provides results traceability. Captures or downloads the lot number, patient/specimen ID, operator ID, and test records using the BD Veritor™ InfoWifi module (optional add-on feature).
Simplifies the testing process. May reduce manual test processing errors with easy operations and single-button functionality.
Achieves reliable, rapid results. Displays easy-to-read digital results for COVID-19 in 15 minutes1, Flu A+B in 15 minutes1, RSV in 10 minutes1 and Group A Strep in 5 minutes1. Provides clear, objective results by correcting for nonspecific binding and detecting faint lines not recognized by the unaided eye.1
Delivers workflow efficiency. Adapts easily to your workflow by offering two operational modes:
Walk away: This allows staff to perform other duties while the sample incubates. Analyze now: Allowing for specimens to be processed in batches.** The Analyzer then performs the analysis and displays the test result.
A 3-in-1 antigen assay for COVID-19, Flu A and Flu B.*
Reliable multiplex results in 15 minutes.1
BD Veritor™ Plus System streamlines clinical and patient workflows by detecting three major respiratory illnesses in one test, reducing the need for multiple sample collections. With multiple testing modes and streamlined workflows, the analyzer empowers convenience and efficiency.
Simplify Flu A+B testing
Streamline your point-of-care flu testing with the portable BD Veritor™ Plus System, which features intuitive operation and timely, reliable results in 10 minutes.1
The BD Veritor™ Plus System offers simple operation, efficient workflows, and reliable, traceable results, which may help improve the patient experience.
CLIA-waived testing for Group A Strep
Achieve accurate Group A Strep results in 5 minutes with the portable, easy-to-use BD Veritor™ Plus System.1
For fast, clear and reliable COVID-19 results, when you need them the most.
Discover the portable, easy-to-use BD Veritor™ Plus System. It provides reliable results in just 15 minutes.1
When your patients need reliable, rapid COVID-19 testing, turn to the BD Veritor™ Plus System. It offers dependable results at the point of care in a simple-to-operate portable instrument.
BD Diagnostic Solutions and Biosciences have combined with Waters Corporation to create a life sciences and diagnostics leader driven by innovation and a relentless commitment to our customers.
As we begin our new journey as part of Waters, there will be no immediate changes in how we serve you. The way you order your products and services and how you process payment for them will not change. Your points of contact for sales, customer service, technical service and support or clinical services will remain the same.
1. BD Veritor™ System for Rapid Detection of Respiratory Syncytial Virus (RSV), package insert, 8086098. Franklin Lakes, NJ: Becton, Dickinson and Company BD Life Sciences, 7 Loveton Circle, Sparks, MD 21152-0999 USA 800-638-8663
*In the USA, the BD Veritor™ System for Rapid Detection of SARS-CoV-2 & Flu A+B has not been FDA cleared or approved but has been authorized by the FDA under an Emergency Use Authorization for use by authorized laboratories; use by laboratories certified under the CLIA, 42 U.S.C. §263a, that meet requirements to perform moderate, high, or waived complexity tests. The product is authorized for use at the Point of Care (POC), i.e., in patient care settings operating under a CLIA Certificate of Waiver, Certificate of Compliance, or Certificate of Accreditation.
This product has been authorized only for the detection of proteins from SARS-CoV-2, influenza A and influenza B, not for any other viruses or pathogens; and, in the USA, the emergency use of this product is only authorized for the duration of the declaration that circumstances exist justifying the authorization of emergency use of in vitro diagnostics for detection and/or diagnosis of COVID 19 under Section 564(b)(1) of the Federal Food, Drug and Cosmetic Act, 21 U.S.C. §360bbb-3(b)(1), unless the declaration is terminated or authorization is revoked sooner.
**The BD Veritor™ RSV CLIA-waived kit is indicated for use in patients under 6 years of age. The BD Veritor™ RSV moderately complex kit is indicated for use in patients under 20 years of age.